autologous dendritic cells electroporated with HIV-1 tat mRNA

Autologous dendritic cells electroporated with HIV-1 tat mRNA (also known as DC-TRN) is an investigational personalized autologous dendritic cell-based therapeutic vaccine. Developed collaboratively by the Vrije Universiteit Brussel and Erasmus MC, Rotterdam, the vaccine consists of autologous monocyte-derived dendritic cells electroporated ex vivo with mRNA encoding the early HIV-1 regulatory proteins Tat, Rev, and Nef (and in some formulations, Gag). These antigen-loaded dendritic cells are designed to present HIV-1 antigens via both MHC class I and class II pathways, thereby priming and expanding HIV-specific CD4+ and CD8+ T-cell responses to control viral replication. In a Phase I/IIa clinical trial in HIV-1-infected patients on stable highly active antiretroviral therapy (HAART), the vaccine was found to be safe and immunogenic, though it did not prevent viral rebound during analytical treatment interruption.

Other names

autologous dendritic cells electroporated with Tat, Rev, and Nef mRNAautologous dendritic cells electroporated with HIV-1 tat, rev, and nef mRNA